Wedge Industrial Co (000534) Fair Value & Analysis
Healthcare · CN · Market cap 15.4B CNY
Fair value as of: Jul 25, 2026
From 9 valuation models · updated 16 days ago
Share price −11.4% over the past month.
Below-average quality, and screening another 77% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥8.04). The favourable scenario is already priced in.
- Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.
How to read this chart
60‑month range ¥8.66 – ¥47.65 · fair‑value band ¥4.82 – ¥8.04 · the ¥27.94 price screens above the ¥6.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 25, 2026.
Analysis
Wedge Industrial Co (000534) currently trades at ¥27.94, while our model-based Fair Value estimate is ¥6.43, implying the stock looks roughly 77.0% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Wedge Industrial Co generated revenue of 1.3B CNY at a net margin of 15.3%. Revenue grew 7.4% year over year. It earns a return on equity of 9.7%. Net debt stands at 1.1B CNY. Fundamentals as of Jul 25, 2026
Our scenario range runs from ¥4.82 (bear case) to ¥8.04 (bull case); at ¥27.94, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 117% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -77%, 000534 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 9 models by family
Widest divergence: Multiples (¥6.43) versus Asset-Based (¥1.79). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 59
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Wedge Industrial Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of micro-ecological live bacteria products, superalloys, and related products in China.
Full company description
Wedge Industrial Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of micro-ecological live bacteria products, superalloys, and related products in China. The company offers micro-ecological preparations, such as bifidobacterium lactobacillus triple live bacteria tablets under the Golden Bifidobacterium brand; vaginal lactobacillus live capsules under the Dingjunsheng brand; dual-span microecological live bacteria drugs under the Jinshuangqi brand; and vaginal microecological live bacteria drug for use in the treatment of gynecological infections under the Dingjunsheng brand. It also provides probiotic products, health food products, probiotic dietary supplements, probiotic hand creams, and other probiotic health products under the Sanlian Probiotics, Bacteria powder, and Today's Bacteria brands. In addition, the company is involved in the research, development, and manufacture of high-temperature alloy materials and core components, including precision casting blades, high temperature alloy powder discs, high temperature master alloys and their alloy powders, and nickel-based high-temperature master alloys. Wedge Industrial Co.,Ltd. was formerly known as Guangdong Wanze Industrial Co., Ltd. and changed its name to Wedge Industrial Co., Ltd. in May 2013. The company was founded in 1992 and is based in Shantou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Wedge Industrial Co reported revenue of ¥1.1B in FY2024 versus ¥553M in FY2020, a compound +18.2%/yr. Reported net income was ¥193M in FY2024, compounding +25.9%/yr from FY2020.
000534 screens 77% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Wedge Industrial Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wedge Industrial Co (000534) overvalued or undervalued?
What is the fair value of 000534?
What is the quality score of 000534?
What is the revenue of Wedge Industrial Co (000534)?
What is the net profit margin of 000534?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Wedge Industrial Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.